Posts by: Steve Bryson PhD

Steve Bryson PhD

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

January 28, 2021January 28, 2021

Study Reveals Molecular Details of Epidiolex Action

uncategorized

Cannabidiol (CBD) — the active ingredient in Epidiolex — was found to bind to and block the opening of the sodium channel protein associated with seizures in people with Lennox-Gastaut ... Read more

November 19, 2020November 19, 2020

Epidiolex-treated LGS Boy Has No Seizures, Near-normal EEG Pattern, Case Study Reports

uncategorized

Adding Epidiolex, an oral cannabidiol medication, to other treatments successfully stopped epileptic seizures in a boy with Lennox-Gastaut syndrome (LGS), resulting in nearly normal electrical activity in the brain, a real-world case ... Read more

November 12, 2020November 12, 2020

Inovelon/Banzel Seen to Treat LGS Seizures Without Hindering Cognition

uncategorized

The add-on anti-seizure therapy Inovelon (rufinamide) shows good tolerability, with one year of treatment not affecting cognitive abilities, adaptive skills, or behavior in children and adults with Lennox-Gastaut syndrome (LGS), ... Read more

October 22, 2020October 22, 2020

Epidiolex Triggers Lithium Toxicity in Boy With LGS, Case Study Reports

News

Epidiolex (cannabidiol) treatment led to lithium toxicity in a boy with Lennox-Gastaut syndrome (LGS), demonstrating a previously unknown, harmful interaction between these two therapies, a case study reports. Given the lack ... Read more

October 1, 2020October 1, 2020

Epidyolex Approved in Scotland to Treat LGS Patients, 2 and Older

uncategorized

The Scottish Medicines Council (SMC) approved Epidyolex (cannabidiol), combined with the anti-epileptic medicine clobazam, as a treatment option for children and adults with Lennox-Gastaut or Dravet Syndrome. Eligible patients, ages ... Read more

August 6, 2020August 6, 2020

Epidiolex Helps Control Seizures in Children Without Affecting Cognition, Study Reports

uncategorized

Epidiolex, a cannabidiol add-on medication for treatment-resistant epilepsy, was safely given to children and teenagers for one year in a clinical trial that included youth with Lennox-Gastaut syndrome, a study reported. ... Read more

June 11, 2020June 11, 2020

MicroRNA-based Gene Therapy Found to Improve Survival in Mouse Model

News

A single gene therapy treatment using microRNAs improved growth and development, and decreased lethal seizures in a mouse model of Lennox-Gastaut syndrome (LGS), a study has found. This proof-of-principle experiment ... Read more

June 4, 2020June 4, 2020

Mouse Model of LGS Created Based on Mutation Found in Patient

uncategorized

Mice created with a single mutation found in a person with Lennox-Gastaut syndrome showed all the hallmarks of the condition, including the same seizure types, and were successfully treated with ... Read more

March 26, 2020March 26, 2020

Spontaneous Mutations Linked to LGS in 2 Boys, Study Reports

uncategorized

Spontaneous mutations affecting a critical protein produced in nerve and muscle cells, called EEF1A2, were found to be the underlying cause of Lennox-Gastaut syndrome (LGS) in two boys in China, a ... Read more

February 13, 2020February 13, 2020

Researchers Pinpoint Novel Genetic Variant as the Cause for LGS and Mild Intellectual Impairments in Korean Family

uncategorized

A previously unknown inherited variation of a gene linked to Lennox-Gastaut Syndrome (LGS) was found as the underlying cause of the condition and mild intellectual disabilities in three generations of ... Read more